XNASNMTC
Market cap25mUSD
Dec 27, Last price
0.82USD
1D
-5.02%
1Q
-19.82%
IPO
-80.76%
Name
Neuroone Medical Technologies Corp
Chart & Performance
P/E
—
P/S
7.30
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
46.60%
Rev. gr., 5y
%
Revenues
3m
+76.86%
Net income
-12m
L+3.87%
CFO
-11m
L-14.55%
Earnings
Feb 11, 2025
Profile
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||||
Revenues | 3,453 76.86% | 1,952 1,040.65% | 171 -3.92% | ||||||||
Cost of revenue | 7,439 | 15,363 | 12,151 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (3,986) | (13,410) | (11,980) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (110) | ||||||||||
Tax Rate | |||||||||||
NOPAT | (3,986) | (13,410) | (11,870) | ||||||||
Net income | (12,318) 3.87% | (11,859) 18.60% | (10,000) 0.52% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 5,871 | 8,471 | 13,351 | ||||||||
BB yield | -22.16% | -52.50% | -49.38% | ||||||||
| Debt | |||||||||||
Debt current | 66 | 129 | 83 | ||||||||
Long-term debt | 455 | 240 | 322 | ||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 2,140 | ||||||||||
Net debt | (940) | (4,954) | (10,736) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (11,012) | (12,887) | (7,520) | ||||||||
CAPEX | (120) | (384) | (275) | ||||||||
Cash from investing activities | (120) | 2,650 | (3,245) | ||||||||
Cash from financing activities | 7,270 | 7,399 | 12,023 | ||||||||
FCF | (4,659) | (13,897) | (11,892) | ||||||||
| Balance | |||||||||||
Cash | 1,460 | 5,322 | 11,141 | ||||||||
Long term investments | |||||||||||
Excess cash | 1,287 | 5,225 | 11,133 | ||||||||
Stockholders' equity | (74,974) | (62,662) | (50,811) | ||||||||
Invested Capital | 78,196 | 69,096 | 60,618 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 26,762 | 18,121 | 15,999 | ||||||||
Price | 0.99 11.19% | 0.89 -47.31% | 1.69 -57.22% | ||||||||
Market cap | 26,495 64.21% | 16,135 -40.32% | 27,038 -36.01% | ||||||||
EV | 25,555 | 11,181 | 16,302 | ||||||||
EBITDA | (3,739) | (13,211) | (11,861) | ||||||||
EV/EBITDA | |||||||||||
Interest | 229 | ||||||||||
Interest/NOPBT | |||||||||||